The Effectiveness and Safety of Dong-A Opalmon® Tablet in Patients With Acquired Lumbar Spinal Stenosis

Last updated: February 25, 2026
Sponsor: Dong-A ST Co., Ltd.
Overall Status: Completed

Phase

N/A

Condition

Spondylolisthesis

Spinal Stenosis

Treatment

N/A

Clinical Study ID

NCT06654856
OMT_LSS_OS
  • Ages > 19
  • All Genders

Study Summary

This study is to evaluate the Effectiveness and Safety of Dong-A Opalmon® Tablet in Patients With Acquired Lumbar Spinal Stenosis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men or women aged ≥ 19 years

  • Subjects with acquired Lumbar Spinal Stenosis who show normal results in theStraight Leg Raising (SLR) test and exhibit intermittent claudication, requiringtreatment with Dong-A Opalmon® tab

  • Subjects who voluntarily consent to participate in this observational study

Exclusion

Exclusion Criteria:

  • Subject for whom the medicinal products administration is contraindicated accordingto the approved domestic drug information: Pregnant women or those who may bepregnant, Subject with genetic disorders such as galactose intolerance, Lapp lactasedeficiency or glucose-galactose malabsorption

  • Subjects considered as unsuitable for participation in this observational study bythe principal investigator or sub-investigator

Study Design

Total Participants: 107
Study Start date:
August 16, 2024
Estimated Completion Date:
February 23, 2026

Connect with a study center

  • VHS Medical Center

    Seoul,
    Korea, Republic of

    Site Not Available

  • VHS Medical Center

    Seoul 1835848,
    South Korea

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.